9-Fluoroprostaglandin derivatives, and use as medicinal agents
Patent 4454339 Issued on June 12, 1984. Estimated Expiration Date: July 6, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/568, Benzene ring nonionically bonded514/247, Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.)514/252.01, 1,2 diazine attached directly or indirectly to an additional hetero ring by nonionic bonding514/252.1, 1,4 diazines514/255.05, Additional hetero ring attached directly or indirectly to the 1,4-diazine ring by nonionic bonding514/269, Pyrimidines with chalcogen bonded directly to a ring carbon of said pyrimidine moiety514/345, Chalcogen bonded directly to ring carbon of the six-membered hetero ring514/369, Chalcogen bonded directly to ring carbon of the thiazole ring514/376, Chalcogen bonded directly to ring carbon of the oxazole ring514/381, Tetrazoles (including hydrogenated)514/432, The hetero ring is six-membered514/473, Chalcogen bonded directly to the hetero ring514/530, Z contains a cyclopentyl or cyclopentene ring514/613, Carboxamides (i.e., R-C(=O)-N, wherein R is a radical having carbon bonded directly to the C(=O)-N or is hydrogen and wherein any substituent attached to nitrogen will be referred to as E)514/617, R contains benzene ring514/63, Silicon containing DOAI514/729, Alicyclic ring containing544/242, 1,3-diazines548/201, The -C(=X)- is part of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens548/215, 1,3-oxazoles (including hydrogenated)549/429, The hetero ring is five-membered549/504, Halogen attached directly or indirectly to the hetero ring by nonionic bonding549/74, Nitrogen attached indirectly to the hetero ring by nonionic bonding549/79, The chalcogen, X, is part of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens556/482, Silicon and carbon bonded directly to the same oxygen560/121, Cyclopentyl in acid moiety (e.g., prostaglandins, etc.)560/17, Sulfur, bonded directly to a ring, in same side chain as ester function560/55, Oxy in acid moiety562/426, Sulfur562/465, Oxy562/504, Cyclopentyl bonded to -COOR, -CCOOR, or -CCCOOR564/175, Oxygen, bonded directly to the benzene ring, is part of an acyclic chain between the benzene ring and the carbonyl564/189, Five-membered ring in substituent Q568/649, Halogen containing568/807Additional ring containing
9-Fluoroprostane derivatives of Formula I ##STR1## wherein R1 is CH2 OH or ##STR2## wherein R2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R1 is the residue ##STR3## wherein R3 is an acid residue or R2 and A is --CH2 --CH2 -- or cis--CH=CH--,B is --CH2 --CH2 --, trans--CH=CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the - or ଲ-position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR6 =CR7 -- wherein R6 and R7 differ from each other and each is hydrogen, chlorine, or alkyl,R4 is a free or functionally modified hydroxy group, andR5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R2 is H, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.
July 6, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
